Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences arcus Biosciences — Deferred collaboration revenue, noncurrent ($M) ($M)
Arcus Biosciences (RCUS) Form 10-Q / 10-K
Latest, Q2 2026
37
Period ended Jun 30, 2026
Change on a year earlier
-38.3%
60 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Deferred collaboration revenue, noncurrent ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 37 | -38.3% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 45 | -79.5% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 43 | -81.6% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 53 | -81.7% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2025 | Jun 30, 2025 | 60 | -72.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 219 | -9.5% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 234 | -23.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 289 | -11.3% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 214 | -35.2% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 242 | -26.7% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 307 | -13.5% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| Q3 2023 | Sep 30, 2023 | 326 | -14.8% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 330 | -23.1% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 330 | -27.8% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 355 | -23.2% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 383 | +304.0% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 429 | +313.2% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 457 | +302.9% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 462 | +248.7% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 94.7 | +3.7% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 104 | +1,122.4% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 113 | +1,001.0% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 133 | +1,004.2% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 91.3 | +561.6% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 8.50 | -19.0% | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 10.3 | -16.3% | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 12 | – | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 13.8 | – | SEC Filing ↗ |
| Q2 2019 | Jun 30, 2019 | 10.5 | – | SEC Filing ↗ |
| Q1 2019 | Mar 31, 2019 | 12.3 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences — Deferred collaboration revenue, noncurrent ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_def_rev_noncur
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.